PerkinElmer, Inc. is a global leader committed to innovating for a healthier world. Our innovative informatics and service capabilities, combined with deep market knowledge and expertise, help customers gain earlier and more accurate insights to improve lives and the world around us. PerkinElmer is the exclusive distributor for both TIBCO Spotfire® and Attivio® for scientific and clinical R&D applications.
940 Winter Street
Waltham, MA 02451
Contact: Rob Rittberg
What is the medical monitor's role in the latest ICH E6 (r2) guidance and how to get them to adopt technology that will help them experience tangible efficiency and quality gains.
In this interview, Jennifer Prichard, MD, Medical Monitor at Atlantic Research Group, and Hunter Walker, CTO at Atlantic Research Group (a CRO) will discuss challenges with existing medical monitoring processes, and how new technologies can help improve efficiency.
The reasons behind the physician monitors’ reluctance, and what technology needs to offer to convince monitors their work can be more efficient — quickly detecting safety signals and speeding time to submission.
Protect the safety of trials subjects and give medical monitors the ability to increase the quality and speed of their work with this solution.
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, recently announced the launch of PerkinElmer Signals Medical Review.
With sponsors facing increasing pressure to reduce drug prices and bring therapies to patients faster, follow these tips to shorten your clinical development process.
The data landscape for clinical operations is complex and comprised of many disparate sources, so a data agnostic solution is essential for full access and visibility into the data. Without an intuitive visual analytics tool, it becomes impossible to navigate data hierarchies and gain meaningful insights into the data.
Insights from medical monitors about the obstacles they face and their impact on the overall study conduct, operational efficiency, and most importantly, subject safety.
To enable the completion of clinical trials as safely, efficiently and quickly as possible, PerkinElmer Informatics’ clinical solutions streamline clinical trial data visualization and analysis with real-time access to clinical data in all phases of clinical development.
Learn about the challenges for Sponsors and CROs when integrating a vast array of data sources, typical relational database structures and why they don’t work for clinical analytics, as well as the ideal clinical data aggregation solutions for continuous, automatic data consolidation.
Learn how PerkinElmer’s clinical solutions give clinical operations organizations the unprecedented ability to reduce the time, cost and risk of running clinical trials while accelerating the time to market for products across the entire portfolio of clinical candidates.
The adoption of RBM is increasing as companies provide greater management support, staff training and more sophisticated technology systems. Technology platforms that enable continuous monitoring with near real-time intuitive visualizations, analytic dashboards and applications will allow issues to be identified and addressed early, improving study safety and efficiency.
Proponents of RBM projects believe that the investment in this approach will return an overall reduction in monitoring expense by 15 to 20 percent. This paper discusses RBM as a high-value use case that can be enhanced by a robust clinical data aggregation and analytics solution.
Drug developers are focusing significant attention on risk-based monitoring (RBM) of clinical trials to improve data quality, trial efficiency and patient safety. Widely encouraged by regulatory agencies, RBM adoption is gradually building momentum as sponsors and contract research organizations (CROs) concentrate on developing the right strategies, deploying the most effective technologies and internally managing change.
Achieve clinical trial operations excellence using this an innovative solution that gives clinical operations organizations the unprecedented ability to reduce the time, cost, and risk of running clinical trials while accelerating time to market for products across the entire portfolio of clinical candidates.
This article discusses ways to adopt patient-centered drug development, changing the corporate culture and trial design, understanding patient needs and incorporating them into trials, and leveraging technology to conduct remote patient-centric clinical trials.